Medpace Holdings (MEDP) Earnings Date & Reports

Key Takeaways

• Medpace Holdings reported third-quarter 2026 revenue of $716.0 million, up 8.5% year over year and slightly ahead of the roughly $714.5 million consensus estimate.
• GAAP diluted earnings per share (EPS) came in at $4.84, beating the analyst consensus of $4.44 by $0.40.
• Net new business awards rose 10.6% to $873.4 million, while backlog grew 5.6% to $3.17 billion.
• Full-year 2026 revenue guidance of $2.835–$2.855 billion landed modestly below consensus at the midpoint, pressuring shares in after-hours trading.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $172.1 million, a 24.0% margin, while the board authorized a new $1.0 billion buyback program.

Earnings Context and Why It Matters

Medpace Holdings, Inc. (NASDAQ: MEDP) is a science-driven clinical contract research organization (CRO) that manages Phase I through IV clinical trials for pharmaceutical, biotechnology, and medical device companies. Its third-quarter report carries outsized weight because the company's premium valuation depends on sustaining strong bookings and backlog growth. Earlier in 2026, weak first-quarter awards sparked investor concern before a record rebound in the second quarter restored confidence and pushed shares to all-time highs. With roughly 95% of revenue tied to biotechnology clients and analysts debating whether growth is moderating, this report serves as a key test of whether Medpace's industry-leading margins and elevated multiple remain justified as the biotech funding cycle matures.

Reported Results

For the three months ended September 30, 2026, Medpace reported net revenue of $716.0 million, an 8.5% increase from $659.9 million in the prior-year period and slightly above the $714.47 million consensus estimate. Net income rose to $137.5 million, or $4.84 per diluted share, compared with $111.1 million, or $3.86 per diluted share, a year earlier. The EPS result beat the $4.44 analyst consensus by $0.40, and net income margin expanded to 19.2% from 16.8%.

On an operating basis, income from operations climbed to $165.5 million, lifting operating margin to 23.1% from 21.5% a year ago. Adjusted EBITDA totaled $172.1 million, representing a 24.0% margin and a 16.0% year-over-year increase. Net new business awards reached $873.4 million, up 10.6% from $789.6 million, while backlog as of September 30, 2026 grew 5.6% to $3,167.2 million from $3,000.6 million.

Management issued full-year 2026 guidance of $2.835 billion to $2.855 billion in revenue, a midpoint of $2.845 billion that fell below the $2.852 billion consensus. GAAP EPS guidance of $17.97 to $18.32, however, topped the $17.72 consensus at the midpoint. The company also announced a new $1.0 billion stock repurchase authorization effective October 20, 2026, replacing the prior program that had $527.0 million remaining.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors monitoring earnings events like Medpace's, the AI Screener offers a structured way to surface new ideas and refine watchlists alongside fundamental research.

Market Reaction and Investor Sentiment

Medpace shares slipped roughly 1.9% in after-hours trading following the report, even though the company beat on both EPS and revenue. The decline reflected investor focus on the full-year revenue outlook, whose midpoint of $2.845 billion came in slightly below the $2.852 billion consensus estimate. The mixed reaction highlights how much of the stock's valuation is tied to the durability of its growth trajectory rather than a single quarter's beat. Heading into the print, analysts maintained a cautious stance, with most rating the stock a hold amid questions about whether its premium forward multiple — among the highest in the CRO group — can be sustained as revenue growth decelerates from recent torrid levels.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will closely watch whether Medpace can convert its rebounding bookings into sustained revenue growth. The company's backlog conversion rate and net book-to-bill ratio (the ratio of new awards to revenue recognized) will be key indicators of near-term demand. A stronger pipeline of net new business awards helps offset prior concerns about slowing backlog coverage, but the modest full-year revenue guidance suggests management remains measured about the pace of acceleration.

Margin trends also merit attention. Medpace's operating margin expansion to 23.1% demonstrates healthy operating leverage, yet analysts have questioned how much of the efficiency gains from artificial intelligence in clinical trials will accrue to CROs versus their pharmaceutical sponsors over time. Sustaining the company's industry-leading profitability will depend on disciplined cost management and favorable pricing.

Finally, biotech funding conditions remain a critical external factor. With the vast majority of Medpace's revenue derived from biotechnology clients, the health of venture capital and public financing for drug developers will influence demand for new trial activity. The new $1.0 billion repurchase authorization signals management's confidence in cash generation, but investors should monitor cash flow, customer concentration, and award momentum in coming quarters as the clearest signals of the company's longer-term trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations